Combination of lenalidomide with dexamethasone (LD) is of high effectiveness for treatment of multiple myeloma (MM),resulting in an improved overall survival,response rate,and time to progression in relapsed or refractory MM. Adverse events,especially venous thromboembolism,were generally well tolerated. In addition,lenalidomide plus dexamethasone is a potential therapy in maintenance of myeloma.